1.The extract of Celtis choseniana Nakai alleviates testosterone-induced benign prostatic hyperplasia through inhibiting 5α reductase type 2 and the Akt/NF-κB/AR pathway.
Geum-Lan HONG ; Tae-Won KIM ; Hui-Ju LEE ; Yae-Ji KIM ; Kyung-Hyun KIM ; Ju-Young JUNG
Chinese Journal of Natural Medicines (English Ed.) 2022;20(7):518-526
Benign prostatic hyperplasia (BPH) is a chronic male disease characterized by the enlarged prostate. Celtis chosenianaNakai (C. choseniana) is medicinally used to alleviate pain, gastric disease, and lung abscess. In this study, the effect of C. choseniana extract on BPH was investigated using testosterone-induced rats. Sprague Dawley rats were divided into five groups: control, BPH (testosterone 5 mg·kg-1), Fina (finasteride 2 mg·kg-1), and C. choseniana (50 and 100 mg·kg-1). After four weeks of TP treatment with finasteride or C. choseniana, prostate weights and DHT levels were measured. In addition, the prostates were histopathologically examined and measured for protein kinase B (Akt)/nuclear factor-κB (NF-κB)/AR signaling, proliferation, apoptosis, and autophagy. Prostate weight and epithelial thickness were reduced in the C. choseniana groups compared with that in the BPH group. The extract of C. choseniana acted as a 5α reductase inhibitor, reducing DHT levels in the prostate. Furthermore, the extract of C. choseniana blocked the activation of p-Akt, nuclear NF-κB activation and reduced the expression of AR and PSA compared with BPH. Moreover, the expression of Bax, PARP-1, and p53 increased, while the expression of bcl-2 decreased. The present study demonstrated that C. choseniana extract alleviated testosterone-induced BPH by suppressing 5α reductase and Akt/NF-κB activation, reducing AR signaling and inducing apoptosis and autophagy in the prostate. These results suggested that C. choseniana probably contain potential herbal agents to alleviate BPH.
Animals
;
Cholestenone 5 alpha-Reductase/metabolism*
;
Finasteride/adverse effects*
;
Male
;
NF-kappa B/genetics*
;
Plant Extracts/therapeutic use*
;
Prostatic Hyperplasia/drug therapy*
;
Proto-Oncogene Proteins c-akt/genetics*
;
Rats
;
Rats, Sprague-Dawley
;
Receptors, Androgen/metabolism*
;
Testosterone
;
Ulmaceae/metabolism*
2.Effects of Kudzu Root plus Cinnamon Granules on prostatic hyperplasia in mice.
An-Xi WANG ; Xiao-Yu ZHU ; Ting HUANG ; Jin YANG ; Yi-Dong CHENG ; Yu-Feng XU
National Journal of Andrology 2017;23(4):353-360
Objective:
To explore the effects of Kudzu Root plus Cinnamon Granules (KR+C) on prostatic hyperplasia (PH) in mice.
METHODS:
Sixty 4-week-old Kunming male mice were randomly divided into six groups: blank control, PH model, high-, medium- and low-dose KR+C, and finasteride control. All the mice except those in the blank control group were subcutaneously injected with testosterone propionate (5 mg / [kg·d]) at 7 days after surgical castration. The animals of different groups were treated intragastrically with different doses of KR+C, finasteride, and normal saline respectively for 3 weeks and then sacrificed for weighing of the prostate, calculation of the prostatic index, observation of the morphological changes in the prostate after HE staining, determination of the expressions of FGF2, Ki67 and TGF-β1 by immunohistochemistry, detection of 5α-reductase activity by ELISA, and measurement of the apoptosis index of the prostatic cells by TUNEL.
RESULTS:
Compared with the model controls, the mice of the other groups showed significantly reduced prostatic volume (P <0.05), prostatic index (P <0.05), expressions of FGF2, Ki67 and TGF-β1, and activity of 5 α-reductase (P <0.05), but remarkably increased apoptosis index of the prostatic cells (P <0.05). However, no statistically significant differences were observed in the above parameters between the finasteride control and the three KR+C groups (P>0.05).
CONCLUSIONS
KR+C can reduce the prostatic volume of PH mice by decreasing the activity of 5α- reductase, inhibiting the expressions of FGF2, Ki67 and TGF-β1, and promoting the apoptosis of prostatic cells.
Animals
;
Apoptosis
;
Cholestenone 5 alpha-Reductase
;
metabolism
;
Cinnamomum zeylanicum
;
chemistry
;
Fibroblast Growth Factor 2
;
metabolism
;
Finasteride
;
therapeutic use
;
In Situ Nick-End Labeling
;
Ki-67 Antigen
;
metabolism
;
Male
;
Mice
;
Organ Size
;
Phytotherapy
;
methods
;
Plant Roots
;
chemistry
;
Prostate
;
pathology
;
Prostatic Hyperplasia
;
drug therapy
;
metabolism
;
pathology
;
Pueraria
;
chemistry
;
Random Allocation
;
Testosterone Propionate
;
administration & dosage
;
Transforming Growth Factor beta1
;
metabolism
;
Urological Agents
;
therapeutic use